Login
Companies $KALA
$3.77 -$0.06 (1.56%) After hours
KALA BIO, Inc. logo

KALA BIO, Inc.

kalarx.com

What Do They Do?

Develops an on-premises AI research platform for biotechnology and pharmaceutical companies, and seeks partners to license its biologic drug candidates.

Who Are Their Customers?

Plans to sell directly to biotechnology and pharmaceutical companies, contract research organizations and academic research institutions; strategic partners and channel arrangements may supplement direct sales.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Net income
▲ +86% (Loss)
vs −$11.2M in Q2 FY2025
  • Sep 3, 2026 KALA agreed to distribute an ophthalmology genetic testing program in the U.S. Virotek will deliver the program; KALA will handle commercial development, and profits will be shared after Virotek recovers product costs.
  • Aug 27, 2026 Nasdaq said KALA failed its minimum bid-price requirement KALA said it would appeal; a timely hearing request pauses suspension or delisting while the panel considers the case.

From drug development to AI The older report centered on developing drug candidates for rare eye diseases; the latest describes an on-premises AI platform for biotech and pharmaceutical clients, while seeking to monetize legacy biologics assets.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support